Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Primary Peritoneal Serous Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01652794
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Who this might be right for
Leydig Cell TumorOvarian SarcomaOvarian Stromal Cancer+10 more
Case Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT01666444
What this trial is testing

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Celgene 297
Early research (Phase 1)Study completedNCT01294293
What this trial is testing

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Who this might be right for
Malignant Ovarian Mixed Epithelial TumorOvarian Brenner TumorOvarian Clear Cell Cystadenocarcinoma+7 more
Gynecologic Oncology Group 20
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Early research (Phase 1)Study completedNCT00005860
What this trial is testing

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT00003380
What this trial is testing

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Early research (Phase 1)Study completedNCT01074411
What this trial is testing

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+17 more
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920798
What this trial is testing

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaPrimary Peritoneal CarcinosarcomaRecurrent Fallopian Tube Carcinoma+13 more
Mayo Clinic 38
Testing effectiveness (Phase 2)Study completedNCT00466960
What this trial is testing

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+9 more
University of Washington 21
Early research (Phase 1)Study completedNCT01459380
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Early research (Phase 1)Study completedNCT03552471
What this trial is testing

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationFolate Receptor Alpha Positive+7 more
Ohio State University Comprehensive Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Not applicableStudy completedNCT00897442
What this trial is testing

Collecting Tumor Samples From Patients With Gynecological Tumors

Who this might be right for
Borderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical Adenocarcinoma+83 more
Gynecologic Oncology Group 275
Large-scale testing (Phase 3)Study completedNCT00003322
What this trial is testing

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 384
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)WithdrawnNCT02627430
What this trial is testing

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeFallopian Tube Serous Neoplasm+10 more
National Cancer Institute (NCI)
Next Page
87